EX-99.2 3 pdfs-20221110xex99d2.htm EX-99.2

a

Exhibit 99.2

Graphic

Q3 2022

Management Report

November 10, 2022

1


Contents

Q3 2022 Results

–  Overview

–  Key Financial & Operating Metrics

–  Revenue by Geographic Area

Q3 2022 Non-GAAP Results

–  Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Income

–  Reconciliation of GAAP to Non-GAAP Spending by Function

Related Information

The following commentary is provided by management and should be referenced in conjunction with PDF Solutions’ third quarter of 2022 financial results press release available on its Investor Relations website at http://www.pdf.com/financial-news. These remarks represent management’s current views of the Company’s financial and operational performance and are provided to give investors and analysts further insight into its performance in advance of the earnings call webcast. The Company disclaims any duty to update this information for future events.

Graphic

2


PDF Solutions Reports Third Quarter 2022 Results

Q3 2022 Key Metrics

financial results Summary

Revenue: $39.9M

GAAP Gross Margin: 69%

    Q3 2022 Total revenues of $39.9M, up 15% over Q2 2022, and up 35% over Q3 2021.

    Q3 2022 Analytics revenue of $32.9M, up 6% over Q2 2022, and up 21% over Q3 2021.

    Q3 2022 Integrated yield ramp revenue of $7.0M, up 97% over Q2 2022 and up 196% over Q3 2021.

Non-GAAP Gross Margin: 72%

GAAP Diluted EPS: $0.04

Non-GAAP Diluted EPS: $0.20

Operating Cash Flow: $1.4M

Cash Used for Capital Expenditures: $2.3M

Graphic

3


Key Financial & Operating Metrics – Quarterly

(in thousands, except share data, which is in millions, and percentages)

Q3’22

  

  

Q2’22

  

  

Q1’22

  

  

Q4’21

  

  

Q3’21

Revenues

$ 39,860

$ 34,668

$ 33,498

$ 29,886

$ 29,555

GAAP Gross Margin

69%

65%

66%

61%

63%

Non-GAAP Gross Margin

72%

69%

69%

65%

66%

Outstanding Debt

 

$ -

 

$ -

$ -

$ -

$ -

Operating Cash Flow

 

$ 1,403

 

$ 3,624

 

$ 2,996

$ 416

$ 4,022

Cash Used for Capital Expenditures (CAPEX)

 

$ 2,118

 

$ 2,822

 

$ 1,765

$ 1,340

$ 1,592

$ Shares Repurchased

 

$ -

 

$ 16,693

 

$ 5,778

$ -

$ -

Weighted Average Common Shares Outstanding

 

37.2

 

37.0

 

37.6

37.3

37.2

Effective Tax Rate Benefit (Expense)

 

(37)%

 

(821)%

 

(40)%

(30)%

(27)%

Graphic

4


Key Financial & Operating Metrics – Year to Date

(in thousands, except share data, which is in millions, and percentages)

Nine Months Ended September 30, 

2022

  

2021

  

2020

Revenues

 

 

$ 108,026

 

$ 81,174

 

$ 65,679

GAAP Gross Margin

 

67%

60%

59%

Non-GAAP Gross Margin

 

70%

64%

64%

Outstanding Debt

 

 

$ -

 

$ -

$ -

Operating Cash Flow

 

 

$ 8,023

 

$ 3,827

 

$ 10,875

Cash Used for CAPEX

 

 

$ 6,705

 

$ 2,713

 

$ 5,365

$ Shares Repurchased

 

 

$ 22,471

 

$ 4,523

 

$ -

Weighted Average Common Shares Outstanding

 

 

37.3

 

37.1

 

33.7

Effective Tax Rate Benefit (Expense)

 

 

(548)%

 

(12)%

 

37%

Graphic

5


Revenue by Geographic Area – Quarterly

(Dollars in thousands)

  

Q3’22

  

Q2’22

  

Q1’22

  

Q4’21

  

Q3’21

United States

 

$ 18,292

$ 17,086

$ 17,491

$ 15,739

$ 13,983

% of Total

 

46%

49%

52%

53%

47%

China

 

$ 9,555

$ 4,539

$ 4,120

$ 4,202

$ 4,038

% of Total

 

24%

13%

12%

14%

14%

Japan

$ 2,818

$ 2,794

$ 2,607

$ 2,554

$ 2,515

% of Total

7%

8%

8%

8%

9%

Rest of the world

 

$ 9,195

$ 10,249

$ 9,280

$ 7,391

$ 9,019

% of Total

 

23%

30%

28%

25%

30%

Total revenues

 

$ 39,860

$ 34,668

$ 33,498

$ 29,886

$ 29,555

Graphic

6


Revenue by Geographic Area – Year to Date

(Dollars in thousands)

  

Nine Months Ended September 30, 

2022

2021

2020

United States

 

$ 52,869

$ 34,634

$ 26,242

% of Total

 

49%

43%

40%

China

 

$ 18,214

$ 10,065

$ 10,200

% of Total

 

17%

12%

16%

Japan

 

$ 8,219

$ 8,543

$ 3,414

% of Total

 

8%

10%

5%

Rest of the world

$ 28,724

$ 27,932

$ 25,822

% of Total

27%

35%

39%

Total revenues

 

$ 108,026

$ 81,174

$ 65,678

Graphic

7


GAAP / Non-GAAP Presentation

In addition to providing results that are determined in accordance with Generally Accepted Accounting Principles in the United States of America (GAAP), the Company also provides certain non-GAAP financial measures. Non-GAAP gross profit excludes stock-based compensation expense and the amortization of acquired technology. Non-GAAP net income excludes the effects of certain non-recurring items, including expenses related to an arbitration proceeding for a disputed customer contract, write-down in value of property and equipment, stock-based compensation expenses, amortization of acquired technology and other acquired intangible assets, and their related income tax effects, as applicable, tax impact of the CARES Act, as well as adjustments for the valuation allowance for deferred tax assets. These non-GAAP financial measures are used by management internally to measure the Company’s profitability and performance. PDF Solutions’ management believes that these non-GAAP measures provide useful supplemental measures to investors regarding the Company’s ongoing operations in light of the fact that none of these categories of expense has a current effect on the future uses of cash (with the exception of expenses related to an arbitration proceeding for a disputed customer contract) nor do they impact the generation of current or future revenues. These non-GAAP results should not be considered an alternative to, or a substitute for, GAAP financial information, and may be different from similarly titled non-GAAP measures used by other companies. In particular, these non-GAAP financial measures are not a substitute for GAAP measures of income or loss as a measure of performance, or to cash flows from operating, investing and financing activities as a measure of liquidity. Management uses these non-GAAP financial measures internally to measure profitability and performance; these non-GAAP measures are presented here to give investors an opportunity to see the Company’s financial results as viewed by management. A detailed reconciliation of the adjustments made to comparable GAAP measures is included herein.

Graphic

8


Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Income

Quarterly

(in thousands, except for shares and per share amounts)

Q3’22

  

Q2’22

  

Q1’22

  

Q4’21

  

Q3’21

GAAP net income (loss)

$ 1,385

($ 1,147)

($ 4,150)

($ 7,000)

($ 2,407)

Adjustments to reconcile GAAP net income (loss) to non-GAAP net income:

Stock-based compensation expense

 

5,136

3,872

5,553

3,457

3,363

Amortization of acquired technology

 

553

553

553

554

454

Amortization of other acquired intangible assets

 

318

314

314

313

314

Expenses of arbitration (1)

 

556

36

451

757

341

Write-down in value of property and equipment (2)

3,183

Tax impact of valuation allowance for deferred tax assets and reconciling items (3)

(373)

664

937

1,539

334

Non-GAAP net income

$ 7,575

$ 4,292

$ 3,658

$ 2,803

$ 2,399

GAAP net income (loss) per diluted share

$ 0.04

($ 0.03)

($ 0.11)

($ 0.19)

($ 0.06)

Non-GAAP net income per diluted share

$ 0.20

$ 0.11

$ 0.09

$ 0.07

$ 0.06

Weighted average common shares used in GAAP net income (loss) per diluted share calculation

38,054

37,028

37,606

37,348

37,221

Weighted average common shares used in Non-GAAP net income per diluted share calculation

 

38,054

37,615

38,580

38,430

37,916


(1)Represents expenses related to an arbitration proceeding over a disputed customer contract, which expenses are expected to continue until the arbitration is resolved.

(2)Pertains to write-down in value of our first-generation of e-beam tools for Design-for-Inspection systems wherein carrying values may not be fully recoverable due to lack of market demand and future needs of our customers for these tools.

(3)The difference between the GAAP and non-GAAP income tax provisions is primarily due to the valuation allowance on a GAAP basis and non-GAAP adjustments. For example, on a GAAP basis, the Company does not receive a deferred tax benefit for foreign tax credits or R&D credits after valuation allowance. The Company’s non-GAAP tax rate and resulting non-GAAP tax expense is not calculated with a full U.S. federal or state valuation allowance due to the Company’s cumulative Non-GAAP income and management’s conclusion that it is more likely than not to utilize its net deferred tax assets (DTAs). Each reporting period, management evaluates the need for a valuation allowance and may place a valuation allowance against its U.S. net DTA on a non-GAAP basis if it concludes it is more likely than not that it will not be able to utilize some or all of its US DTAs on a non-GAAP basis.

Graphic

9


Reconciliation of GAAP Net Loss to Non-GAAP Net Income

Year to Date

(in thousands, except for shares and per share amounts)

  

Nine Months Ended September 30, 

2022

2021

2020

GAAP net loss

 

($ 3,912)

($ 14,488)

($ 6,914)

Adjustments to reconcile GAAP net loss to non-GAAP net income:

 

Stock-based compensation expense

 

14,561

9,474

9,476

Amortization of acquired technology

 

1,660

1,525

431

Amortization of other acquired intangible assets

 

945

942

521

Expenses of arbitration (1)

 

1,043

1,194

830

Write-down in value of property and equipment

311

Tax impact of reconciling items

(1,931)

Tax impact of the CARES Act (2)

(2,261)

Tax impact of valuation allowance for deferred tax assets and reconciling items (3)

1,228

1,552

Non-GAAP net income

$ 15,525

$ 199

$ 463

GAAP net loss per diluted share

($ 0.10)

($ 0.39)

($ 0.21)

Non-GAAP net income per diluted share

$ 0.41

$ 0.01

$ 0.01

Weighted average common shares used in GAAP net income (loss) per diluted share calculation

37,285

37,067

33,696

Weighted average common shares used in Non-GAAP net income per diluted share calculation

38,082

37,723

34,705


(1)Represents expenses related to an arbitration proceeding over a disputed customer contract, which expenses are expected to continue until the arbitration is resolved.

(2)The Company recognized a discrete tax benefit recognized from the carryback of net operating losses (NOLs) under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) enacted in March 2020. Due to the full valuation allowance against U.S. DTA recognized in the fourth quarter of 2020, there is no tax benefit from the released tax attributes. The Company does not have any NOLs on a non-GAAP basis and, therefore, it did not recognize this discrete tax benefit in calculating its non-GAAP tax expense and net income (loss).

(3)The difference between the GAAP and non-GAAP income tax provisions is primarily due to the valuation allowance on a GAAP basis and non-GAAP adjustments. For example, on a GAAP basis, the Company does not receive a deferred tax benefit for foreign tax credits or R&D credits after valuation allowance. The Company’s non-GAAP tax rate and resulting non-GAAP tax expense is not calculated with a full U.S. federal or state valuation allowance due to the Company’s cumulative Non-GAAP income and management’s conclusion that it is more likely than not to utilize its net deferred tax assets (DTAs). Each reporting period, management evaluates the need for a valuation allowance and may place a valuation allowance against its U.S. net DTA on a non-GAAP basis if it concludes it is more likely than not that it will not be able to utilize some or all of its US DTAs on a non-GAAP basis.

Graphic

10


Reconciliation of GAAP to Non-GAAP Spending by Function

Quarterly

(in thousands)

Q3’22

  

Q2’22

  

Q1’22

  

Q4’21

  

Q3’21

Cost of Revenue - GAAP

 

$ 12,545

$ 12,042

$ 11,529

$ 11,675

$ 11,070

Adjustments to reconcile GAAP Cost of Revenue to Non-GAAP Cost of Revenue:

 

Stock-based compensation expense

 

(854)

(655)

(728)

(703)

(670)

Amortization of acquired technology

 

(553)

(553)

(553)

(554)

(454)

Cost of Revenue - Non-GAAP

 

$ 11,138

$ 10,834

$ 10,248

$ 10,418

$ 9,946

Research & Development - GAAP

 

$ 14,303

$ 13,374

$ 14,089

$ 11,218

$ 10,657

Adjustments to reconcile GAAP R&D to Non-GAAP R&D:

Stock-based compensation expense

(2,180)

(1,810)

(3,168)

(1,502)

(1,299)

Research & Development - Non-GAAP

$ 12,123

$ 11,564

$ 10,921

$ 9,716

$ 9,358

Selling, General, & Administrative - GAAP

$ 12,005

$ 9,770

$ 10,839

$ 9,167

$ 9,609

Adjustment to reconcile GAAP SG&A to Non-GAAP SG&A:

Stock-based compensation expense

(2,102)

(1,407)

(1,657)

(1,252)

(1,394)

Expenses of arbitration (1)

(556)

(36)

(451)

(757)

(341)

Selling, General, & Administrative - Non-GAAP

 

$ 9,347

$ 8,327

$ 8,731

$ 7,158

$ 7,874


(1)Represents expenses related to an arbitration proceeding over a disputed contract with a customer, which expenses are expected to continue until the arbitration is resolved.

Graphic

11


Reconciliation of GAAP to Non-GAAP Spending by Function

Year to Date

(in thousands)

Nine Months Ended September 30, 

2022

  

2021

  

2020

Cost of Revenue - GAAP

 

$ 36,116

$ 32,518

$ 26,926

Adjustments to reconcile GAAP Cost of Revenue to Non-GAAP Cost of Revenue:

 

Stock-based compensation expense

 

(2,237)

(1,860)

(2,582)

Amortization of acquired technology

 

(1,660)

(1,525)

(431)

Cost of Revenue - Non-GAAP

 

$ 32,219

$ 29,133

$ 23,913

Research & Development - GAAP

 

$ 41,766

$ 32,562

$ 24,672

Adjustments to reconcile GAAP R&D to Non-GAAP R&D:

Stock-based compensation expense

(7,158)

(4,013)

(3,613)

Write-down in value of property and equipment

(149)

Research & Development - Non-GAAP

$ 34,608

$ 28,549

$ 20,910

Selling, General, & Administrative - GAAP

$ 32,614

$ 28,482

$ 24,052

Adjustment to reconcile GAAP SG&A to Non-GAAP SG&A:

Stock-based compensation expense

(5,166)

(3,601)

(3,281)

Expenses of arbitration (1)

(1,043)

(1,194)

(830)

Write-down in value of property and equipment

(162)

Selling, General, & Administrative - Non-GAAP

 

$ 26,405

$ 23,687

$ 19,779


(1)Represents expenses related to an arbitration proceeding over a disputed contract with a customer, which expenses are expected to continue until the arbitration is resolved.

Graphic

12